.webp)
- Liyaga Suresh Babu
Regeneron Pharmaceuticals collaborates with TriNetX to integrate genomic, proteomic, and EHR data for AI-driven drug discovery innovation.
A significant breakthrough is happening in the biopharmaceutical and life sciences sectors due to the collaboration between Regeneron Pharmaceuticals, Inc. and TriNetX, where the parties plan to integrate genomic and proteomic big data with a global Electronic Health Record (EHR) network. The initiative is important because of its significance for precision medicine data integration for translational research and drug discovery platforms using AI. According to the agreement, Regeneron will gain unique access to the anonymized healthcare data collected about over 300 million people in various countries with a total number of 170 million cases registered in the US population. Combining such data with the RGC® genomic and proteomic information will help to develop larger and more accurate EHR-connected databases.
TriNetX will collect longitudinal and anonymized information in accordance with all regulatory requirements related to HIPAA and GDPR regulations. This collaboration might result in significant advancements in the development of research based on real-world evidence generation for personalized medicine, machine learning applications in clinical genomics, and analytics. According to Jeff Margolis, TriNetX Executive Chairman, this alliance would enhance federated health data networks through the analysis of the global clinical data. Aris Baras, MD, Senior Vice President & Head of RGC, pointed out that this alliance would aid Regeneron in developing the world's biggest database related to genomics and proteomics linked with electronic health records. This will result in the creation of next-generation digital solutions for patients, physicians, and consumers.
In this deal, Regeneron is committing $200 million to enable TriNetX to develop its innovations on drug targets through artificial intelligence and health data analytics. According to experts, this collaboration has the potential of setting standards on biomedical data infrastructure integration as well as accelerating advances in complex diseases. Business Honor thinks that the above collaboration is an example of the benefits that can be derived from the integration of advanced genomics, proteomics, and electronic health record data coupled with AI analytics.
About the Author
Liyaga Suresh Babu is a skilled writer known for creating clear, engaging, and informative content. With a strong attention to detail, Liyaga simplifies complex ideas into easy-to-understand insights. Passionate about delivering value to readers, her writing combines accuracy with clarity, aiming to inform, engage, and make content accessible and meaningful to a wide audience across diverse topics.
.webp)
